Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.
Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC.
Strand MS, et al. Among authors: wickline sa.
Oncotarget. 2019 Jul 30;10(46):4761-4775. doi: 10.18632/oncotarget.27109. eCollection 2019 Jul 30.
Oncotarget. 2019.
PMID: 31413817
Free PMC article.